Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR
Lars Dyrskjøt(Aarhus University Hospital), Torben F. Ørntoft(Aarhus University Hospital), Tahlita C.M. Zuiverloon(Erasmus MC), Núria Malats(Spanish National Cancer Research Centre), Ellen C. Zwarthoff(Erasmus MC), Francisco X. Real(Universitat Pompeu Fabra), Joseph A. Sorge(Decisive Analytics Corporation (United States)), Alexey Novoradovsky(Decisive Analytics Corporation (United States)), Margaret A. Knowles(St James's University Hospital), Michael Borre(Aarhus University), Ulrika Segersten(Uppsala University), Willemien Beukers(Erasmus University Rotterdam), Thomas Reinert(Aarhus University Hospital), Carolyn D. Hurst(University of Leeds)
Cited by 40
Related Papers
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
|JAMA Oncology|2019|992
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Intragenic ERBB2 kinase mutations in tumours
|Nature|2004|790
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654